Performance of Sanofi Pasteur in 1Q17
Sanofi Pasteur reported revenue growth of 22.2% at constant exchange rates to 784 million euros during 1Q17.
Revenues from Sanofi’s Established Prescription Products rose 0.6% at constant exchange rates during 1Q17 and reported revenues of ~2.6 billion euros in 1Q17.
Sanofi’s (SNY) Generics business contributes ~5% to the group’s total revenues.
Sanofi Pasteur’s revenues rose 22.2 % at constant exchange rates to 784 million euros during 1Q17.
Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.
Sanofi’s Diabetes and Cardiovascular franchise reported revenues of ~1.4 billion euros in 1Q17.
Paris-based Sanofi (SNY) reported revenues of ~8.7 billion euros in 1Q17. Sanofi surpassed analyst estimates, posting EPS of 1.42 euros in 1Q17, compared to estimates of 1.31 euros.
Merck’s (MRK) Animal Health segment operates in more than 140 countries worldwide. Global sales in 1Q17 were $939.0 million, a 13.0% rise from 1Q16.
Remicade, a top-selling drugs for the treatment of inflammatory disorders, is losing market share after the loss of exclusivity in European markets in February 2015.
Gardasil is Merck’s (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16.
Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.
Merck’s Pharmaceutical segment contributed nearly 86.7% of the company’s total revenues in 1Q17 compared to 87.0% in 1Q16.
Keytruda was launched by Merck in 4Q14 and reported global sales of $584.0 million in 1Q17. That was a 134.0% growth compared to $249.0 million in 1Q16.
Merck’s 1Q17 revenues were mainly driven by Gardasil, Keytruda, Proquad/Varivax, and its animal health products.
Merck stock has risen nearly 16.0% over the last 12 months. Analysts estimate that the stock has a potential to return 10.0% over the next 12 months.
Bristol-Myers Squibb’s (BMY) oncology and cardiovascular products were among the most prioritized brands in the company’s total portfolio in 1Q17.
Eliquis is a new blockbuster drug in Bristol-Myers Squibb’s portfolio, and its sales rose ~50% to $1.1 billion in 1Q17.
Bristol-Myers Squibb’s (BMY) latest drug Opdivo was the seventh drug to be approved by the FDA for the treatment of melanoma.
Daklinza and Sunvepra are the two drugs in BMY’s Hepatitis C franchise. Revenues from these drugs fell to $162 million in 1Q17.
Opdivo reported ~60% growth in revenues to just over $1.1 billion in 1Q17, as compared to $704 million in 1Q16.